Infinity Pharmaceuticals Inc expected to post a loss of 12  cents a share - Earnings Preview

Infinity Pharmaceuticals

07/05/2021 14:43

* Infinity Pharmaceuticals Inc  INFI.OQ   INFI.O  is expected
to show a rise in quarterly revenue when it reports results on
May 13 .
* The Cambridge, Massachusetts-based company is expected to
report   a 168.2% increase in revenue to $1.148 million from
$428 thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Infinity
Pharmaceuticals Inc is for a loss of 12 cents per share. For the
same quarter last year, the company reported a loss of 19 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had fallen by
about 0.4% in the last three months. ​
* Wall Street's median 12-month price target for Infinity
Pharmaceuticals Inc is $8​, about 62.6% above​ its last closing
price of $2.99. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.16       -0.16      -0.16     Met     -2.1
 Sep. 30 2020  -0.15       -0.16      -0.16     Met     -2.6
 Jun. 30 2020  -0.20       -0.19      -0.16     Beat    16.1​
 Mar. 31 2020  -0.12       -0.13      -0.19     Missed  -43.7
 Dec.          -0.19​      -0.19      -0.20     Missed  -4.7​
 31​ 2019​                                              
 Sep. 30 2019  -0.13       -0.10      -0.20     Missed  -109.4
                                                        ​
 Jun. 30 2019  -0.15       -0.07      -0.18     Missed  -173.8
 Mar. 31 2019  -0.03       -0.05      -0.24     Missed  -414.2
 This summary was machine generated May 7 at 13:43 GMT.  All
figures in US dollars unless otherwise stated